Stemline Therapeutics, Inc.
STML
STML was delisted on the 9th of June, 2020.
69 hedge funds and large institutions have $166M invested in Stemline Therapeutics, Inc. in 2015 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 38 increasing their positions, 10 reducing their positions, and 7 closing their positions.
409% more call options, than puts
Call options by funds: $524K | Put options by funds: $103K
280% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 10
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
28% more capital invested
Capital invested by funds: $130M → $166M (+$36.3M)
11% more funds holding
Funds holding: 62 → 69 (+7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$8.84M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$7.27M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$7.27M |
| 4 |
TCM
TimesSquare Capital Management
New York
|
+$7.22M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$5.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$2.55M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$406K |
| 3 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
-$364K |
| 4 |
Goldman Sachs
New York
|
-$302K |
| 5 |
CIA
Capital Impact Advisors
Boston,
Massachusetts
|
-$173K |
STML Hedge Fund Activity: Q1 2015 in Review
69 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q1 2015, worth a combined $166M — up 28% from $130M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new STML positions and 7 closed out — a net gain of 7 holders — while 38 added to existing stakes and 10 trimmed.
The largest buyer was Farallon Capital Management, adding an estimated $8.84M. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $2.55M sold.
- 69 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q1 2015, up from 62 in Q4 2014.
- Funds reported $166M of Stemline Therapeutics, Inc. stock for Q1 2015, up 28% quarter-over-quarter.
- 14 funds opened new Stemline Therapeutics, Inc. positions in Q1 2015 and 7 closed out, a net change of +7 holders.
- The largest Stemline Therapeutics, Inc. buyer in Q1 2015 was Farallon Capital Management, an estimated $8.84M added.
- The largest Stemline Therapeutics, Inc. seller in Q1 2015 was Balyasny Asset Management, an estimated $2.55M sold.
Based on aggregated 13F filings for Q1 2015.